The Annual General Meeting of Active Biotech was held on May 19, 2022. Due to the situation resulting from the Corona virus, the Meeting was carried out through postal voting, without any physical...
Active Biotech's Annual Report 2021 is now available for download at www.activebiotech.com. The Annual Report will only be digitally distributed. Download as PDF Lund, April 28, 2022 Active...
Lund, April 26, 2022, Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the European Patent Office (EPO) has issued a decision to grant Active Biotech’s patent related to use of laquinimod as treatment of eye diseases associated with excessive vascularization. The patent will be granted on May 11, 2022, under patent number EP 3886858, and provides protection and market exclusivity of laquinimod in this field of use until 2040. A similar application is pending in the US Patent Office.
FIRST QUARTER IN BRIEF Dr. Erik Vahtola appointed Chief Medical Officer (Jan 01)First patient dosed in the combination part of the phase Ib/IIa study of tasquinimod in multiple myeloma (Feb...
The shareholders of Active Biotech AB (publ) are invited to the Annual General Meeting of shareholders to be held on Thursday, May 19, 2022. Due to the situation resulting from the Corona virus, the...
The number of shares and votes in Active Biotech has changed as a result of allotment of performance shares under the company’s incentive program for the company’s employees (Plan 2020/2024). Today,...
The correction refers to the administrative costs for the period January – December 2021 that due to oversight have been stated too low. The incorrect amount was SEK 14,0 M, the correct amount is SEK...
Active Biotech announced it has entered into an exclusive license agreement with Oncode Institute in the Netherlands, for the global rights to patents relating to the use of tasquinimod and other inhibitors of S100 for use in treatment of myelofibrosis (MF).
In 2021, we made substantial progress in our projects to address unmet medical need in hematological cancers and inflammatory eye disorders. The fourth quarter in particular proved to be a busy period, with continued strong development with all the prioritized projects in our portfolio.
Lund Sweden, February 7, 2022 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the first patient has been dosed in the combination part of the phase Ib/IIa clinical study of tasquinimod in relapsed or refractory multiple myeloma. In this part of the study treatment with tasquinimod will be tested together with the orally administered antimyeloma agents ixazomib, lenalidomide, and dexamethasone (IRd).